Literature DB >> 7536356

Cell death and cell cycle perturbation in the developmental toxicity of the demethylating agent, 5-aza-2'-deoxycytidine.

J M Rogers1, B M Francis, K K Sulik, A J Alles, E J Massaro, R M Zucker, K H Elstein, M B Rosen, N Chernoff.   

Abstract

DNA methylation is a probable mechanism for regulating gene expression, and alterations in methylation may significantly affect embryonic development. We administered the cytidine analogue 5-aza-2'-deoxycytidine (dAZA), a specific and potent demethylator of DNA, to pregnant mice to determine its teratogenicity and effects on embryonic cell death and cell cycle. Groups of females were dosed intraperitoneally on gestation day 10 with doses of 0.05-3 mg/kg dAZA and killed at 4, 8, or 28 hr later. Two embryos per litter were immediately stained with Nile blue sulfate (NBS) to identify areas of cell death; the remaining embryos were frozen and stored for subsequent flow cytometric (FCM) analysis of the cellular DNA synthetic cycle in limb buds. A dose-related accumulation of cells in the S and G2/M phases was observed at 4 and 8 hr after maternal dosing. S-phase accumulation was the most sensitive indicator of effect; a dose-related increase in the percentage of hindlimb bud cells in S-phase was evident at all dosages 4 hr after maternal dosing. By 28 hr postdosing, a normal cell cycle phase distribution was observed at doses of < 0.3 mg/kg. However, cell cycle perturbations persisted at higher dosages. NBS staining demonstrated increased cell death in areas of rapid cell division, indicative of replication-associated cytotoxicity, at doses of > or = 0.1 mg/kg. Observation of litters from additional dams killed at term revealed that at dosages of > or = 0.3 mg/kg, cleft palate and hindlimb defects were significantly elevated. In addition, above 0.3 mg/kg, fetal weight was significantly decreased.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7536356     DOI: 10.1002/tera.1420500504

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  8 in total

1.  Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; Dennis R Warner; Irina A Smolenkova; M Michele Pisano; Robert M Greene
Journal:  Reprod Toxicol       Date:  2016-12-05       Impact factor: 3.143

2.  Bone loss in adult offspring induced by low-dose exposure to teratogens.

Authors:  Arkady Torchinsky; Limor Mizrahi; Shoshana Savion; Ron Shahar; Vladimir Toder; Eugene Kobyliansky
Journal:  J Bone Miner Metab       Date:  2011-09-30       Impact factor: 2.626

Review 3.  Developmental epigenetics of the murine secondary palate.

Authors:  Ratnam S Seelan; Partha Mukhopadhyay; M Michele Pisano; Robert M Greene
Journal:  ILAR J       Date:  2012

4.  Fluorescence-based high-throughput assay for human DNA (cytosine-5)-methyltransferase 1.

Authors:  Yu Ye; James T Stivers
Journal:  Anal Biochem       Date:  2010-03-01       Impact factor: 3.365

5.  Determinants of orofacial clefting I: Effects of 5-Aza-2'-deoxycytidine on cellular processes and gene expression during development of the first branchial arch.

Authors:  Partha Mukhopadhyay; Ratnam S Seelan; Francine Rezzoug; Dennis R Warner; Irina A Smolenkova; Guy Brock; M Michele Pisano; Robert M Greene
Journal:  Reprod Toxicol       Date:  2016-11-30       Impact factor: 3.143

6.  Cytosine methylation and mammalian development.

Authors:  C P Walsh; T H Bestor
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

7.  MicroRNA-34a is dispensable for p53 function as teratogenesis inducer.

Authors:  Eyal Mor; Lin He; Arkady Torchinsky; Noam Shomron
Journal:  Arch Toxicol       Date:  2014-03-13       Impact factor: 5.153

8.  Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy.

Authors:  Frauke Nitzki; Ezequiel J Tolosa; Nicole Cuvelier; Anke Frommhold; Gabriela Salinas-Riester; Steven A Johnsen; Martin E Fernandez-Zapico; Heidi Hahn
Journal:  Oncotarget       Date:  2015-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.